27-03-2019
Jonathan Weiss / Shutterstock.com
The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Eli Lilly, Cialis, erectile dysfunction, Teva, Mylan, Actavis, patent validity, UK Supreme Court, Cilias, tadalafil
Eli Lilly avoids sanctions in Teva migraine treatment dispute
13-01-2022
Eli Lilly enters $35m immunology R&D deal
25-04-2019
Eli Lilly defeat shows one size does not fit all in obviousness test: lawyers
28-03-2019
Eli Lilly defeated as Cialis patent found obvious on appeal
01-11-2017
Eli Lilly settles Cialis patent litigation with generic makers
18-07-2017
